Upcoming
Webinar

 

Real world case studies: Predicting pharmacokinetics from limited ADME data with deep learning

Thursday, 9 February 2023 – 4.00PM (GMT), 11.00AM (EST), 8:00AM (PST)

To become a successful drug, our active molecule must also display excellent pharmacokinetic (PK) properties, however experimental data on PK parameters can be difficult to come by.

In our previous webinar, Predicting Pharmacokinetic Parameters and Curves we explored a proof-of-concept example of how deep learning imputation can help us to accurately predict PK, even when we may not have much experimental data.

Now, join Matt Segall, PhD, CEO at Optibrium, as he introduces a real world case study where we applied deep learning to guide a project, in which potential compounds were displaying good activity profiles but the team wanted to improve their PK profile to achieve better efficacy.

Find out more about:

  • The challenges we face in using data in drug discovery
  • What deep learning imputation is, and how it works in the context of PK
  • Real life case studies of deep learning in action for PK prediction, and how our collaborators have found success using these methods
  • Optibrium’s Cerella AI drug discovery software

Following the presentation there will be an interactive Q&A session, so please come prepared with any questions specific to your area of interest!

Register to attend this webinar

Matthew Segall PhD

CEO and Company Director

Matt has a Master of Science in computation from the University of Oxford and a PhD in theoretical physics from the University of Cambridge. As Associate Director at Camitro (UK), ArQule Inc. and then Inpharmatica, he led a team developing predictive ADME models and state-of-the-art intuitive decision-support and visualization tools for drug discovery. In January 2006, he became responsible for management of Inpharmatica’s ADME business, including experimental ADME services and the StarDrop software platform. Following acquisition of Inpharmatica, Matt became Senior Director responsible for BioFocus DPI’s ADMET division and in 2009 led a management buyout of the StarDrop business to found Optibrium.